Ocular Therapeutix, Inc.

NasdaqGM:OCUL Stock Report

Market Cap: US$1.3b

Ocular Therapeutix Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:OCUL Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
25 Nov 24SellUS$16,326Sanjay NayakIndividual1,814US$9.00
25 Nov 24SellUS$186,327Pravin DugelIndividual20,680US$9.01
25 Nov 24SellUS$26,102Peter KaiserIndividual2,897US$9.01
25 Nov 24SellUS$26,561Jeffrey HeierIndividual2,948US$9.01
23 Aug 24SellUS$16,525Sanjay NayakIndividual1,832US$9.02
23 Aug 24SellUS$188,338Pravin DugelIndividual20,880US$9.02
23 May 24SellUS$13,280Sanjay NayakIndividual2,274US$5.84
23 May 24SellUS$125,215Pravin DugelIndividual21,626US$5.79
26 Feb 24BuyUS$7,000,000Summer Road LLCCompany930,851US$7.52
05 Feb 24SellUS$95,460Antony MattessichIndividual19,642US$4.86
05 Feb 24SellUS$30,190Donald NotmanIndividual6,212US$4.86
05 Feb 24SellUS$30,842Rabia OzdenIndividual6,346US$4.86
05 Feb 24SellUS$29,301Philip StrassurgerIndividual6,029US$4.86
05 Feb 24SellUS$28,723Christopher WhiteIndividual5,910US$4.86
31 Jan 24SellUS$90,773Antony MattessichIndividual18,338US$4.95
31 Jan 24SellUS$33,813Philip StrassurgerIndividual6,831US$4.95
31 Jan 24SellUS$31,843Donald NotmanIndividual6,433US$4.95
31 Jan 24SellUS$25,478Christopher WhiteIndividual5,147US$4.95
31 Jan 24SellUS$38,432Rabia OzdenIndividual7,764US$4.95

Insider Trading Volume

Insider Buying: OCUL insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of OCUL?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1,191,1160.758%
Hedge Funds8,060,0005.13%
General Public17,977,19811.4%
VC/PE Firms25,483,92216.2%
Institutions104,505,19166.5%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 42.6%.

Top Shareholders

Top 25 shareholders own 74.58% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
9.16%
Summer Road LLC
14,398,193US$115.0m-3.27%98.62%
8.12%
VR Adviser, LLC
12,762,462US$102.0m0%7.73%
8.09%
Deep Track Capital, LP
12,721,460US$101.6m0%3.27%
7.22%
BlackRock, Inc.
11,354,164US$90.7m-1.44%no data
5.33%
The Vanguard Group, Inc.
8,384,183US$67.0m-2.65%no data
5.13%
Avoro Capital Advisors LLC
8,060,000US$64.4m0%0.93%
3.38%
TCG Crossover Management, LLC
5,319,148US$42.5m0%4.41%
3.2%
Opaleye Management Inc.
5,025,000US$40.1m-5.32%7.12%
2.71%
Citadel Advisors LLC
4,259,838US$34.0m5.08%0.04%
2.39%
Adage Capital Management, L.P.
3,750,000US$30.0m1.49%0.05%
2.23%
Logos Global Management, L.P.
3,500,000US$28.0m-32%3.93%
2.21%
State Street Global Advisors, Inc.
3,476,292US$27.8m-11.3%no data
2.11%
Perceptive Advisors LLC
3,324,468US$26.6m0%0.65%
2.08%
Geode Capital Management, LLC
3,271,207US$26.1m-5.24%no data
1.65%
Deltec Asset Management LLC
2,600,073US$20.8m0.38%3.73%
1.54%
Octagon Capital Advisors LP
2,425,000US$19.4m0%3.29%
1.42%
Braidwell LP
2,239,770US$17.9m36.3%0.82%
1.3%
Point72 Asset Management, L.P.
2,040,620US$16.3m-24.6%0.04%
0.99%
Morgan Stanley, Investment Banking and Brokerage Investments
1,562,320US$12.5m40.9%no data
0.79%
Northern Trust Global Investments
1,246,697US$10.0m15.5%no data
0.76%
Acuta Capital Partners, LLC
1,190,071US$9.5m-57.1%9.49%
0.74%
Franklin Resources, Inc.
1,170,047US$9.3m0%no data
0.71%
Charles Schwab Investment Management, Inc.
1,110,460US$8.9m0%no data
0.67%
Artisan Partners Limited Partnership
1,056,092US$8.4m0%0.01%
0.64%
Woodline Partners LP
1,000,000US$8.0m0%0.07%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/23 23:46
End of Day Share Price 2025/01/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ocular Therapeutix, Inc. is covered by 21 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Anita DushyanthBerenberg
Tazeen AhmadBofA Global Research